Clinical trials: Healthy Subjects;Overweight or Obesity
Obesity
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
The purposes of this study are to: Find out how much of the study drugs are in the blood of healthy subjects after taking multiple doses of VI-0521, metformin and sitagliptan.
- Trial name
- NCT00842400
- Testing
- Metformin, VI-0521, Sitagliptan, Probenecid
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Overweight, Healthy Participants
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults.
- Conditions
- Overweight, Healthy Participants, Obesity
- Trial name
- NCT07793019
- Testing
- Orforglipron, IBI3042
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy, Overweight and/or Obese Subjects
Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects
Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects
- Trial name
- NCT01764425
- Testing
- P7435
- Where
- 2 sites in India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Healthy Participants
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234.
- Trial name
- NCT07220954
- Testing
- AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration)
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
This Phase 1, first-in-human study will evaluate the safety and tolerability of SUN-0864, how the body processes SUN-0864, and how SUN-0864 affects the body in healthy adults and otherwise healthy adults who are overweight or…
- Trial name
- NCT07905560
- Testing
- SUN-0864 (Formulation 1) or SUN-0864 (Formulation 2)
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Superluminal Medicines, Inc.
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
- Trial name
- NCT00551564
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight or Obesity, Type2 Diabetes Mellitus
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study…
- Trial name
- NCT05762471
- Testing
- GSBR-1290
- Where
- 4 sites in United States
- Volunteers
- 142 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Overweight, Obesity
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
This study is open to adults between 18 and 55 years of age with overweight or obesity. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) has an effect on cardiac safety.
- Trial name
- NCT06200467
- Testing
- BI 456906, Moxifloxacin
- Where
- Germany
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single or multiple oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single or multiple oral dose.
- Trial name
- NCT01444677
- Testing
- MB12066
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Overweight, Obesity
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity.
- Trial name
- NCT07437079
- Testing
- NNC6989-0001
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Obesity
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance
Agonistic activation of fat metabolite responsive G-protein-coupled receptors (GPCR) has been linked to improved glucose metabolism through increased glucose-stimulated-insulin-secreting (GSIS) and incretin release, improved…
- Trial name
- NCT03774095
- Testing
- Hydrolyzed pine nut oil, Hydrolyzed pine nut oil and olive oil
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Karina Vejrum Sørensen
Obesity
A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM and is an agonist for both glucagon-like…
- Trial name
- NCT02692781
- Testing
- MOD-6031
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.
- Trial name
- NCT01146327
- Testing
- PF-04620110
- Where
- 2 sites in Belgium, Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Volunteers
High-intensity Interval Training on the Self-esteem, Basal Metabolic Rate and Muscle Mass in Overweight Women.
Overweight and obesity are a public health problem for society, reflected by an increase in its prevalence worldwide, being more frequent in women and related to low levels of self-esteem, accumulation of subcutaneous fat and…
- Trial name
- NCT03852043
- Testing
- High-intensity interval training, Moderate-intensity continuous training
- Where
- Colombia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Universidad de Antioquia
Healthy, Non-diabetic Overweight or Obese
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese…
- Trial name
- NCT07239973
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.